Sales of Smoking Cessation Products Reach $1 Billion

Smoking cessation product sales reached $1 billion last year in the United States, according to the market research firm Mintel. Sales are expected to reach $1.2 billion by 2017, according to

“As more Americans put out their cigarettes, the market for smoking cessation products is expected to grow, despite challenging economic circumstances; however, smoking cessation brands face certain challenges,” Mintel Health and Wellness Analyst Emily Krol noted in a news release. “A declining number of smokers, as well as increased smoking bans and taxes on cigarettes are shrinking the market of potential users. Growth opportunities for this market will be found in product innovation and line extensions.”

According to Mintel, 41 percent of smokers interested in quitting say they would consider trying over-the-counter nicotine sprays, and 41 percent want to try a prescription nicotine inhaler. Forty percent say they would use over-the-counter nicotine replacement lozenges, and 38 percent would like to use nicotine-free cigarettes.

Some smokers are also intrigued by non-nicotine replacement methods including hypnosis (35 percent), acupuncture (34 percent) and individual therapy or a smoking cessation support group (37 percent). In addition, 30 percent said they are willing to try a quit-smoking app on their smartphone or tablet.

    User Picture


    January 4, 2013 at 3:28 PM

    And I don’t know a single person who has quit who credits the patches and gums. Since the stuff does not seem to work, I guess people are supposed to buy it repeatedly, then blame themselves when they go back to smoking. It’s the yoyo between smoking and gummy/patching that’s making the big money for pharma.

    User Picture


    January 4, 2013 at 1:58 PM

    RWJF did good! They’ve funded JoinTogether, the ACS, ALA, Michael Fiore (UW), Stanton Glantz (UCSF), Stephen Schroeder (former CEO of RWJF who left with a $10mil grant for the “smoking cessation leadership center), and others who push the need for their parent company Johnson & Johnson’s Nicorette, Nicoderm, Nicoderm CQ (pretty much all the OTC NRT products). I’d say it was a pretty good ROI, since RWJF also owns JnJ stock. But I’m pretty sure my comments won’t make it to this board, since JT also got RWJF funding. Now THIS is a RICO investigation I’d pay money to sit in the audience to hear.

Leave a Reply

Your email address will not be published. Required fields are marked *